Discovery of Cationic Lugdunin Derivatives with Membrane-Disrupting Activity against Resistant Bacteria via Radical Reactions and Amino Acid Mutations
Journal of Medicinal Chemistry · 13.03.2025 · 68 (5) · 5699-5718
DOI: 10.1021/acs.jmedchem.4c03020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 21.02.2025. Verfasst von Yuhang He und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, West Donggang Road 199, La…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Microbial Sensitivity Tests, Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Lanzhou University, Lanzhou Science and Technology Bureau, National Natural Science Foundation of China.
Abstract (Originalsprache)
Lugdunin was the first reported new class of thiazolidine cyclopeptide antibiotic from human microbiomes. However, its structure could not accommodate polar amino acids or modules, limiting its potential for chemical modification and clinical application. Herein, we developed a combinatorial modification strategy based on in situ modification of tryptophan through a radical reaction and amino acid site-specific mutation, transforming lugdunin into a cationic cyclic peptide antibiotic. Among the derivatives of lugdunin, WK6 was identified as a highly potent membrane-active antibiotic with rapid bactericidal activity and low resistance development potential. Remarkably, it showed therapeutic efficacy in MRSA-infected murine models of keratitis, pneumonia, and peritonitis. Additionally, when grafted onto contact lens Surfaces, WK6 exhibited potent antifouling capabilities, highlighting its potential in implant antifouling applications. Therefore, this study developed an effective strategy to optimize lugdunin and unveiled a novel cationic lugdunin derivative WK6, which could be recognized as a promising lead compound to combat multidrug-resistant bacteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Preclinical Study for New Drugs of Gansu Province, School of Basic Medical Sciences, Lanzhou University, West Donggang Road 199, Lanzhou 730000, P. R. China.
ORCID-Profile: Wenjin Yan, Kairong Wang
Förderung
- Lanzhou University
- Lanzhou Science and Technology Bureau
- National Natural Science Foundation of China
- Natural Science Foundation of Gansu Province
Zitieren
APA
He, Y., Su, J., Li, M., Fareed, M. S., Ren, Y., Wang, P., Wang, Z., Wan, D., Ma, T., Yan, W., Zhang, H., & Wang, K. (2025). Discovery of Cationic Lugdunin Derivatives with Membrane-Disrupting Activity against Resistant Bacteria via Radical Reactions and Amino Acid Mutations. Journal of Medicinal Chemistry, 68(5), 5699-5718. https://doi.org/10.1021/acs.jmedchem.4c03020
Vancouver
He Y, Su J, Li M, Fareed MS, Ren Y, Wang P, et al. Discovery of Cationic Lugdunin Derivatives with Membrane-Disrupting Activity against Resistant Bacteria via Radical Reactions and Amino Acid Mutations. Journal of Medicinal Chemistry. 2025;68(5):5699-5718. doi:10.1021/acs.jmedchem.4c03020
BibTeX
@article{He2025,
author = {He, Yuhang and Su, Jie and Li, Min and Fareed, Muhammad S and Ren, Yixuan and Wang, Panpan and Wang, Zhaopeng and Wan, Daicao and Ma, Ting and Yan, Wenjin and Zhang, Hailong and Wang, Kairong},
title = {Discovery of Cationic Lugdunin Derivatives with Membrane-Disrupting Activity against Resistant Bacteria via Radical Reactions and Amino Acid Mutations},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {5},
pages = {5699--5718},
doi = {10.1021/acs.jmedchem.4c03020}
}
EUVIMED